American heart journal

publication venue for

Should we routinely supplement coronary patients with folate therapy to prevent in-stent restenosis? 2005
Progressive dehiscence and dynamic compression of an aortic root homograft: detection and characterization by transesophageal echocardiography. 1996
Masking of echocardiographic mitral valve prolapse during evolution of dilated cardiomyopathy. 1993
Intracardiac thrombi in patients undergoing electroconvulsive therapy. 1990
Mid-cavity obstruction in apical hypertrophy: Doppler evidence of diastolic intraventricular gradient with higher apical pressure. 1988
Carcinoid heart disease presenting as right-to-left shunt and congestive heart failure: successful surgical treatment. 1988
Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design. 2024
Rationale and design of the NODE-303 study: Evaluating the safety of symptom-prompted, self-administered etripamil for paroxysmal supraventricular tachycardia episodes in real-world settings. 2024
Influence of left ventricular ejection fraction in patients undergoing contemporary pLVAD-supported high-risk PCI.. 269. 2024
Quality and rapidity of anticoagulation in patients with acute pulmonary embolism undergoing mechanical thrombectomy.. 267. 2024
Design and rationale of the evaluation of transcatheter aortic valve replacement compared to surveillance for patients with asymptomatic severe aortic stenosis: The EARLY TAVR trial.. 268. 2023
Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE.. 264. 2023
Rationale and design of the Dynamic Coronary Roadmap for Contrast Reduction (DCR4Contrast) in PCI randomized controlled trial.. 263. 2023
Postoperative pericardial effusion, pericardiotomy, and atrial fibrillation: An explanatory analysis of the PALACS trial.. 260. 2023
Design and rationale of re-energize fontan: Randomized exercise intervention designed to maximize fitness in fontan patients.. 259. 2023
Rationale and design of BROKEN-SWEDEHEART: a registry-based, randomized, parallel, open-label multicenter trial to test pharmacological treatments for broken heart (takotsubo) syndrome.. 257. 2022
Primary left ventricular unloading with delayed reperfusion in patients with anterior ST-elevation myocardial infarction: Rationale and design of the STEMI-DTU randomized pivotal trial.. 254. 2022
Inflammation biomarkers and incident coronary heart disease: The Reasons for Geographic and Racial Differences in Stroke Study. 2022
Rationale and design of switch Swedeheart: A registry-based, stepped-wedge, cluster-randomized, open-label multicenter trial to compare prasugrel and ticagrelor for treatment of patients with acute coronary syndrome.. 251. 2022
Balance of benefit and risk of ticagrelor in patients with diabetes and stable coronary artery disease according to bleeding risk assessment with the CRUSADE score: Data from THEMIS and THEMIS PCI.. 249. 2022
Randomized evaluation of vessel preparation with orbital atherectomy prior to drug-eluting stent implantation in severely calcified coronary artery lesions: Design and rationale of the ECLIPSE trial.. 249. 2022
Fibroblast growth factor-23 and subclinical markers of cardiac dysfunction: The coronary artery risk development in young adults (CARDIA) study.. 245. 2021
Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations.. 241. 2021
Advanced heart failure patients supported with ambulatory inotropic therapy: What defines success of therapy?. 239. 2021
Randomized comparison of early supplemental oxygen versus ambient air in patients with confirmed myocardial infarction: Sex-related outcomes from DETO2X-AMI.. 237. 2021
Cardiac transplantation outcomes in patients with amyloid cardiomyopathy.. 236. 2021
The associations between direct and delayed critical care unit admission with mortality and readmissions among patients with heart failure.. 233. 2020
Outcomes following revascularization with radial artery bypass grafts: Insights from the PREVENT-IV trial.. 228. 2020
In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events.. 225. 2020
Mild sleep restriction increases 24-hour ambulatory blood pressure in premenopausal women with no indication of mediation by psychological effects.. 223. 2020
Long-term clinical outcomes with use of an angiotensin-converting enzyme inhibitor early after heart transplantation.. 222. 2020
The effect of metoprolol and aspirin on cardiovascular risk in bereavement: A randomized controlled trial.. 220. 2019
Association of 25-hydroxyvitamin D with incident coronary heart disease in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study.. 217. 2019
C-reactive protein and stroke risk in blacks and whites: The REasons for Geographic And Racial Differences in Stroke cohort.. 217. 2019
Expanding opportunities to understand quality and outcomes of peripheral vascular interventions: The ACC NCDR PVI Registry.. 216. 2019
The OPTIMIZE randomized trial to assess safety and efficacy of the Svelte IDS and RX Sirolimus-eluting coronary stent Systems for the Treatment of atherosclerotic lesions: Trial design and rationale.. 216. 2019
Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial.. 215. 2019
Incidence and predictors of target lesion failure in patients undergoing contemporary DES implantation-Individual patient data pooled analysis from 6 randomized controlled trials.. 213. 2019
Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study.. 211. 2019
C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: Analysis from the EXCEL trial.. 210. 2019
Telephone-based mindfulness training to reduce stress in women with myocardial infarction: Rationale and design of a multicenter randomized controlled trial.. 202. 2018
Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction.. 201. 2018
Comparison of automated interval measurements by widely used algorithms in digital electrocardiographs.. 200. 2018
Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial.. 199. 2018
Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients.. 198. 2017
Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study.. 197. 2017
Fine particulate matter and incident coronary heart disease in the REGARDS cohort.. 197. 2017
Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial.. 197. 2017
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.. 196. 2017
Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE-AF) randomized trial: Design and rationale.. 190. 2017
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.. 188. 2017
Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome.. 187. 2017
Time to achieving therapeutic international normalized ratio increases hospital length of stay after heart valve replacement surgery.. 187. 2017
The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.. 185. 2016
Diabetes mellitus is a coronary heart disease risk equivalent for peripheral vascular disease.. 184. 2016
Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial.. 182. 2016
Diabetes, diabetes severity, and coronary heart disease risk equivalence: REasons for Geographic and Racial Differences in Stroke (REGARDS).. 181. 2016
Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial.. 179. 2016
Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction.. 180. 2016
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.. 178. 2016
Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial.. 178. 2016
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.. 177. 2016
High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction.. 171. 2015
Variation in use of echocardiography among veterans who use the Veterans Health Administration vs Medicare.. 170. 2015
Rationale and design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: a comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with multivessel coronary artery disease.. 170. 2015
Rationale and design of the Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial.. 170. 2015
Comparison of quality-of-life measures after radial versus femoral artery access for cardiac catheterization in women: Results of the Study of Access Site for Enhancement of Percutaneous Coronary Intervention for Women quality-of-life substudy.. 170. 2015
Trends in mortality and recurrent coronary heart disease events after an acute myocardial infarction among Medicare beneficiaries, 2001-2009.. 170. 2015
Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration.. 169. 2015
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.. 169. 2015
Sensitive troponin assays in patients with suspected acute coronary syndrome: Results from the multicenter rule out myocardial infarction using computer assisted tomography II trial.. 169. 2015
A nationwide survey on perception, experience, and expectations of hybrid coronary revascularization among top-ranked US hospitals.. 169. 2015
Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial.. 169. 2015
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.. 168. 2014
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.. 168. 2014
Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cells.. 168. 2014
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER).. 168. 2014
Association of metabolic syndrome and its individual components with outcomes among patients with high-risk non-ST-segment elevation acute coronary syndromes.. 168. 2014
Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry.. 167. 2013
The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study.. 167. 2013
Rationale and design of Faith-based Approaches in the Treatment of Hypertension (FAITH), a lifestyle intervention targeting blood pressure control among black church members.. 167. 2013
Prognostic implications of procedural vs spontaneous myocardial infarction: results from the Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry.. 166. 2013
Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial.. 166. 2013
Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial.. 166. 2013
Risk for recurrent coronary heart disease and all-cause mortality among individuals with chronic kidney disease compared with diabetes mellitus, metabolic syndrome, and cigarette smokers.. 166. 2013
Red cell distribution width as a bleeding predictor after percutaneous coronary intervention.. 166. 2013
A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study.. 165. 2013
Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy.. 165. 2013
Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome.. 165. 2013
Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: an analysis from ACT34-CMI.. 164. 2012
Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results.. 164. 2012
Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.. 164. 2012
Multi-marker strategy of natriuretic peptide with either conventional or high-sensitivity troponin-T for acute coronary syndrome diagnosis in emergency department patients with chest pain: from the "Rule Out Myocardial Infarction using Computer Assisted Tomography" (ROMICAT) trial.. 163. 2012
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.. 163. 2012
Design of the Rule Out Myocardial Ischemia/Infarction Using Computer Assisted Tomography: a multicenter randomized comparative effectiveness trial of cardiac computed tomography versus alternative triage strategies in patients with acute chest pain in the emergency department.. 163. 2012
Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction.. 163. 2012
Mode of death after contemporary percutaneous coronary intervention: a report from the Evaluation of Drug Eluting Stents and Ischemic Events registry.. 162. 2011
Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function.. 162. 2011
The National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC): results from phase I and scientific opportunities in phase II.. 162. 2011
A multicenter comparison of established and emerging cardiac biomarkers for the diagnostic evaluation of chest pain in the emergency department.. 162. 2011
Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction".. 162. 2011
Incidence and clinical outcome of minor surgery in the year after drug-eluting stent implantation: results from the Evaluation of Drug-Eluting Stents and Ischemic Events Registry.. 161. 2011
Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY.. 160. 2010
Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial.. 160. 2010
Rapid adoption of drug-eluting stents: clinical practices and outcomes from the early drug-eluting stent era.. 160. 2010
Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease.. 160. 2010
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI).. 160. 2010
Heart rate is associated with red blood cell fatty acid concentration: the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study.. 159. 2010
Variations in prevalent cardiovascular disease and future risk by metabolic syndrome classification in the REasons for Geographic and Racial Differences in Stroke (REGARDS) study.. 159. 2010
Impact of computerized dosing on eptifibatide-associated bleeding and mortality.. 158. 2009
Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial.. 158. 2009
Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial.. 158. 2009
Rationale and design of the Duke Electrophysiology Genetic and Genomic Studies (EPGEN) biorepository.. 158. 2009
Association of aortic valve calcification to the presence, extent, and composition of coronary artery plaque burden: from the Rule Out Myocardial Infarction using Computer Assisted Tomography (ROMICAT) trial.. 158. 2009
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.. 158. 2009
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.. 157. 2009
Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography.. 157. 2009
Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry.. 157. 2009
Implantable cardioverter-defibrillator deactivation at the end of life: a physician survey.. 157. 2009
Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial.. 157. 2009
Adverse association between diabetic retinopathy and cardiac structure and function.. 157. 2008
Platelet reactivity and response to aspirin in subjects with the metabolic syndrome.. 156. 2008
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.. 157. 2008
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.. 156. 2008
Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome.. 156. 2008
Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes.. 155. 2008
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II--study design and rationale.. 155. 2008
Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes.. 155. 2007
Ethnicity and socioeconomic status influence use of primary angioplasty in patients presenting with acute myocardial infarction.. 154. 2007
Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease.. 154. 2007
Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.. 154. 2007
Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.. 154. 2007
Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease.. 153. 2007
Documented traditional cardiovascular risk factors and mortality in non-ST-segment elevation myocardial infarction.. 153. 2007
Effect of oral beta-blocker therapy on microvolt T-wave alternans and electrophysiology testing in patients with ischemic cardiomyopathy.. 153. 2007
Platelet reactivity in patients with subacute stent thrombosis compared with non-stent-related acute myocardial infarction.. 153. 2007
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.. 152. 2006
Trends in acute myocardial infarction complicated by cardiogenic shock, 1979-2003, United States.. 152. 2006
Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes--the Stop Atherosclerosis in Native Diabetics Study (SANDS).. 152. 2006
Clinical correlates of long-term mortality after percutaneous interventions of saphenous vein grafts.. 152. 2006
Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative.. 152. 2006
Impact of organizational infrastructure on beta-blocker and aspirin therapy for acute myocardial infarction.. 152. 2006
Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.. 152. 2006
Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.. 152. 2006
The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes.. 151. 2006
Effects of a statewide physician-led quality-improvement program on the quality of cardiac care.. 151. 2006
Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.. 151. 2006
Recursive partitioning-based preoperative risk stratification for atrial fibrillation after coronary artery bypass surgery.. 151. 2006
Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: the Strong Heart Study (SHS).. 151. 2006
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials.. 151. 2006
Impact of race and ethnicity on inhospital outcomes after percutaneous coronary intervention (report from the 2000-2001 New York State Angioplasty Registry).. 151. 2006
Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era.. 150. 2005
The effects of enhanced external counterpulsation on myocardial perfusion in patients with stable angina: a multicenter radionuclide study.. 150. 2005
Identification of a novel 5-base pair deletion in calcineurin B (PPP3R1) promoter region and its association with left ventricular hypertrophy.. 150. 2005
Percent change in B-type natriuretic peptide levels during treadmill exercise as a screening test for exercise-induced myocardial ischemia.. 150. 2005
The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics.. 150. 2005
Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).. 150. 2005
The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.. 149. 2005
Two-year clinical follow-up of 90Sr/90 Y beta-radiation versus placebo control for the treatment of in-stent restenosis.. 149. 2005
Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes.. 149. 2005
Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative.. 148. 2004
Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.. 148. 2004
Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.. 148. 2004
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.. 148. 2004
Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT.. 148. 2004
Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction.. 147. 2004
Economic impact of drug-eluting stents on hospital systems: a disease-state model.. 147. 2004
Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes.. 147. 2004
Impact of infarct size on clinical and echocardiographic outcome in patients undergoing nonsurgical septal reduction therapy.. 146. 2003
Influence of thrombolytic therapy, with or without intra-aortic balloon counterpulsation, on 12-month survival in the SHOCK trial.. 146. 2003
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.. 146. 2003
Prognostic implications of ejection fraction from linear echocardiographic dimensions: the Strong Heart Study.. 146. 2003
Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.. 146. 2003
Associations of aortic and mitral regurgitation with body composition and myocardial energy expenditure in adults with hypertension: the Hypertension Genetic Epidemiology Network study.. 145. 2003
Comparison of rotational atherectomy with conventional balloon angioplasty in the prevention of restenosis of small coronary arteries: results of the Dilatation vs Ablation Revascularization Trial Targeting Restenosis (DART).. 145. 2003
Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.. 145. 2003
Adjusting for patient differences in predicting hospital mortality for percutaneous coronary interventions in the Clinical Outcomes Assessment Program.. 145. 2003
Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the Strong Heart Study.. 145. 2003
Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials.. 145. 2003
Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.. 144. 2002
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).. 144. 2002
Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension.. 144. 2002
Associations between angiotensinogen gene variants and left ventricular mass and function in the HyperGEN study.. 143. 2002
Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).. 143. 2002
Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists.. 143. 2002
Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide.. 143. 2002
Myocardial function and geometry in hypertensive subjects with low levels of afterload.. 143. 2002
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial.. 143. 2002
Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction.. 143. 2002
Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial.. 143. 2002
Relationship of impaired glucose tolerance to left ventricular structure and function: The Strong Heart Study.. 141. 2001
Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study.. 141. 2001
A population-based assessment of left ventricular systolic dysfunction in middle-aged and older adults: the Strong Heart Study.. 141. 2001
Dalteparin in combination with abciximab during percutaneous coronary intervention.. 141. 2001
Prognostic implications of left ventricular hypertrophy.. 141. 2001
Formal analysis of the optimal duration of tilt testing for the diagnosis of neurally mediated syncope.. 141. 2001
Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions.. 140. 2000
Underutilization of oral anticoagulant therapy for stroke prevention in elderly patients with heart failure.. 140. 2000
Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial.. 139. 2000
Age and outcome after acute coronary syndromes without persistent ST-segment elevation.. 139. 2000
Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.. 139. 2000
Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators.. 139. 2000
Protruding aortic arch atheromas: risk of stroke during heart surgery with and without aortic arch endarterectomy.. 138. 1999
Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention.. 138. 1999
Is all unstable angina the same? insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). The CAVEAT-Investigators.. 137. 1999
Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion.. 137. 1999
Heart rate changes preceding ventricular ectopy in patients with ventricular tachycardia caused by reentry, triggered activity, and automaticity.. 136. 1998
Progressive deterioration of coronary flow reserve after heart transplantation.. 136. 1998
Coronary flow reserve may predict myocardial recovery after myocardial infarction in patients with TIMI grade 3 flow.. 136. 1998
Effects of intraaortic balloon counterpulsation on carotid artery blood flow.. 135. 1998
Effects of adenosine on left ventricular filling dynamics in patients with and without coronary artery disease: a Doppler echocardiographic study.. 135. 1998
Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial.. 135. 1998
Precordial QT dispersion and inducible ventricular tachycardia.. 134. 1997
Transthoracic three-dimensional echocardiographic reconstruction of left and right ventricles: in vitro validation and comparison with magnetic resonance imaging.. 133. 1997
Novel delivery system for verapamil designed to achieve maximal blood pressure control during the early morning.. 132. 1996
Reduction in angioplasty complications after the introduction of coronary stents: results from a consecutive series of 2242 patients.. 132. 1996
Combined rest and exercise electrocardiographic repolarization findings in relation to structural and functional abnormalities in asymptomatic aortic regurgitation.. 132. 1996
Lack of association between mitral valve prolapse and history of rheumatic fever.. 131. 1996
Vascular effects of diet-induced hypercalcemia after balloon artery injury in giant Flemish rabbits.. 130. 1995
Performance of the signal-averaged electrocardiogram: relation to baseline QRS duration.. 129. 1995
Lymphocyte G proteins reflect response to treatment in congestive heart failure.. 129. 1995
Differential therapeutic responses of patients with isoproterenol-dependent and isoproterenol-independent vasodepressor syncope.. 128. 1994
Electrocardiographic repolarization measurements at rest and during exercise in normal subjects and in patients with coronary artery disease.. 128. 1994
Normalization of cardiac structure and function after regression of cardiac hypertrophy.. 128. 1994
Dobutamine stress echocardiography: sensitivity, specificity, and predictive value for future cardiac events.. 127. 1994
Transesophageal echocardiography in critically ill patients: feasibility, safety, and impact on management.. 127. 1994
Prostaglandin E1 does not accelerate rTPA-induced thrombolysis in acute myocardial infarction.. 127. 1994
Population selection and performance of the exercise ECG for the identification of coronary artery disease.. 127. 1994
Assessment of regional myocardial perfusion with myocardial contrast echocardiography in a canine model of varying degrees of coronary stenosis.. 127. 1994
Comparison of teboroxime and thallium for the reversibility of exercise-induced myocardial perfusion defects.. 126. 1993
Acceleration of atrioventricular conduction during corticosteroid therapy.. 125. 1993
Value and limitations of heart rate-adjusted ST segment depression criteria for the identification of anatomically severe coronary obstruction: test performance in relation to method of rate correction, definition of extent of disease, and beta-blockade.. 125. 1993
Doppler assessment of right ventricular filling dynamics in systemic hypertension: comparison with left ventricular filling.. 124. 1992
Contrast opacification of left ventricular myocardium following intravenous administration of sonicated albumin microspheres.. 122. 1991
Effect of atenolol on myocardial infarct expansion in a nonreperfused rat model.. 122. 1991
Use of adenosine echocardiography for diagnosis of coronary artery disease.. 122. 1991
The effect of enteric-coated aspirin on the morning increase in platelet activity.. 121. 1991
Hypertensive heart disease: relationship of silent ischemia to coronary artery disease and left ventricular hypertrophy.. 120. 1990
Factors influencing the outcome of balloon aortic valvuloplasty in the elderly.. 120. 1990
Comparative accuracy of Doppler echocardiographic methods for clinical stroke volume determination.. 120. 1990
Effect of baseline ST segment elevation on test performance of standard and heart rate-adjusted ST segment depression criteria.. 119. 1990
Superiority of warfarin over aspirin long term after thrombolytic therapy for acute myocardial infarction.. 119. 1990
Comparison of quantitative coronary angiography to visual estimates of lesion severity pre and post PTCA.. 119. 1990
Relationship of atrial natriuretic factor to left ventricular volume and mass.. 118. 1989
Reversal of left ventricular dilatation, hypertrophy, and dysfunction by valve replacement in aortic regurgitation.. 118. 1989
The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio.. 118. 1989
Prognostic significance of the signal-averaged ECG depends on the time of recording in the postinfarction period.. 118. 1989
Nonventricular arrhythmias as precursors of ventricular fibrillation in patients with out-of-hospital cardiac arrest.. 118. 1989
Effect of ambulatory blood pressure monitoring on the diagnosis and cost of treatment for mild hypertension.. 116. 1988
Accurate assessment of aortic stenosis severity by Doppler echocardiography independent of aortic jet velocity.. 116. 1988
Identification of anatomically extensive coronary artery disease by the exercise ECG ST segment/heart rate slope.. 115. 1988
Prevalence and clinical correlates of non-Wenckebach, narrow-complex second-degree atrioventricular block detected by ambulatory ECG.. 115. 1988
Ambulatory monitoring of blood pressure as a predictor of cardiovascular risk.. 114. 1987
Assessment of left ventricular diastolic filling by two-dimensional echocardiography.. 113. 1987
Mitral valve prolapse and infective endocarditis.. 113. 1987
Relationship of the electrocardiographic response to exercise to geometric and functional findings in aortic regurgitation.. 113. 1987
Evaluation of coronary artery disease by an improved method of exercise electrocardiography: the ST segment/heart rate slope.. 112. 1986
Hemodynamic effects of moricizine at rest and during supine bicycle exercise: results in patients with ventricular tachycardia and left ventricular dysfunction.. 112. 1986
Relation between the presence of echocardiographic vegetations and the complication rate in infective endocarditis.. 112. 1986
Mitral valve prolapse and hyperthyroidism: effect of patient selection.. 110. 1985
Mitral-septal angle: a new two-dimensional echocardiographic index of left ventricular performance.. 110. 1985
Electrophysiologic evaluation of syncope in patients with bifascicular block.. 106. 1983
Mitral valve prolapse in the general population. 1. Epidemiologic features: the Framingham Study.. 106. 1983
Mitral valve prolapse in the general population. 2. Clinical features: the Framingham Study.. 106. 1983
Mitral valve prolapse in the general population. 3. Dysrhythmias: the Framingham Study.. 106. 1983
Ethmozine suppression of single and repetitive ventricular premature depolarizations during therapy: documentation of efficacy and long-term safety.. 106. 1983
Effect of cardiac surgery on ventricular septal motion: assessment by intraoperative echocardiography and cross-sectional two-dimensional echocardiography.. 104. 1982
Reliable estimation of peak left ventricular systolic pressure by M-mode echographic-determined end-diastolic relative wall thickness: identification of severe valvular aortic stenosis in adult patients.. 103. 1982
Septal myocardial perfusion imaging with thallium-201 in the diagnosis of proximal left anterior descending coronary artery disease.. 102. 1981
Effect of exercise training on plasma high-density lipoprotein cholesterol in coronary disease patients.. 101. 1981
Sequential postoperative assessment of left ventricular performance with gated cardiac blood pool imaging following aortocoronary bypass surgery.. 101. 1981
The control of hypertension in the community: no easy solution.. 97. 1979
Hemorrhagic myocardial infarction associated with aortocoronary bypass revascularization.. 96. 1978
Aortic valve closure: echocardiographic, phonocardiographic, and hemodynamic assessment.. 91. 1976
An analysis of the left ventricular response to isometric exercise.. 88. 1974
What do we mean by "outcome can be predicted"?. 156. 2008
Dynamic QT dispersion during exercise.. 136. 1998
Hypertension control: an alternative view from Gimbels.. 96. 1978
Low left ventricular outflow tract velocity time integral predicts normotensive shock in patients with acute pulmonary embolism. 2024
Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment. 2014
Detection of abnormal LV function in mitral regurgitation by echographic mitral-septal separation. 1982
Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. 2009
Conflict of interest. 2004
When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials.. 189. 2017
Resistance or resistors? Has Ohm's law come to antiplatelet therapy?. 159. 2010
An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design.. 159. 2010
Revascularization of coronary atherosclerosis in patients with diabetes mellitus--there is more to it than meets the image intensifier.. 149. 2005
On the matter of method in exercise testing.. 127. 1994
Autonomic dysfunction in early breast cancer: Incidence, clinical importance, and underlying mechanisms. 2015
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. 2012
The Cardiac Safety Research Consortium electrocardiogram warehouse: thorough QT database specifications and principles of use for algorithm development and testing. 2010
Efficacy and safety of catheter-based thrombectomy versus catheter-directed thrombolysis in acute pulmonary embolism. 2024
International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. 2018
The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. 2015
Rescuing clinical trials in the United States and beyond: a call for action. 2013
Noninvasive, medical management for non-ST-elevation acute coronary syndromes. 2008
Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction. 2006
Changing the model of care for patients with acute coronary syndromes. 2003
Therapeutic options in minimizing left ventricular hypertrophy. 2000
Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes. 1999
Acute myopericarditis resulting from Lyme disease. 1995
Recombinant tissue-type plasminogen activator: current concepts and guidelines for clinical use in acute myocardial infarction. Part II. 1991
Relationship between ambulatory and exercise blood pressure and cardiac structure. 1988
Role of Doppler and imaging echocardiography in selection of patients for cardiac valvular surgery. 1987
Arrhythmias and sudden death in mitral valve prolapse. 1987
Diagnosis and classification of severity of mitral valve prolapse: methodologic, biologic, and prognostic considerations. 1987
Recombinant tissue-type plasminogen activator: current concepts and guidelines for clinical use in acute myocardial infarction. Part I. 1991

VIVO Weill Cornell Medical College

American heart journal Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)